An update on the health benefits of green tea

Beverages

Volumn 3, Issue 1, 2017, Pages

  Reygaert, Wanda C ^a  

^a OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

Author keywords

Anti inflammatory; Anticarcinogenic; Antimicrobial; Antioxidant; Cardiovascular disease; Green tea; Oral health

Indexed keywords

EID: 85019565902     PISSN: None     EISSN: 23065710     Source Type: Journal    
DOI: 10.3390/beverages3010006     Document Type: Review

References (113)

1. Gupta, D.A.; Bhaskar, D.J.; Gupta, R.K.; Karim, B.; Jain, A.; Dalai, D.R. Green tea: A review on its natural anti-oxidant therapy and cariostatic benefits. Biol. Sci. Pharm. Res. 2014, 2, 8–12.
2. Jigisha, A.; Nishant, R.; Navin, K.; Pankaj, G. Green tea: A magical herb with miraculous outcomes. Int. Res. J. Pharm. 2012, 3, 139–148.
3. Cabrera, C.; Artacho, R.; Gimenez, R. Beneficial effects of green tea—A review. J. Am. Coll. Nutr. 2006, 25, 79–99. [CrossRef] [PubMed]
4. Botten, D.; Fugalio, G.; Fraternali, F.; Molteni, C. Structural properties of green tea catechins. J. Phys. Chem. B 2015, 119, 12860–12867. [CrossRef] [PubMed]
5. Hayat, K.; Iqbal, H.; Malik, U.; Bilal, U.; Mushtaq, S. Tea and its consumption: Benefits and risks. Crit. Rev. Food Sci. Nutr. 2015, 55, 939–954. [CrossRef] [PubMed]
6. Wang, Y.; Ho, C.T. Polyphenolic chemistry of tea and coffee: A century of progress. J. Agric. Food Chem. 2009, 57, 8109–8114. [CrossRef] [PubMed]
7. Roowi, S.; Stalmach, A.; Mullen, W.; Lean, M.E.; Edwards, C.A.; Crozier, A. Green tea flavan-3-ols: Colonic degradation and urinary excretion of catabolites by humans. J. Agric. Food Chem. 2010, 58, 1296–1304. [CrossRef] [PubMed]
8. Babu, P.V.; Liu, D. Green tea catechins and cardiovascular health: An update. Curr. Med. Chem. 2008, 15, 1840–1850. [CrossRef] [PubMed]
9. Fernandez, P.L.; Pablos, F.; Martin, M.J.; Gonzalez, A.G. Study of catechin and xanthine tea profiles as geographical tracers. J. Agric. Food Chem. 2002, 59, 1833–1839. [CrossRef]
10. Lin, Y.S.; Tsai, Y.J.; Tsay, J.S.; Lin, J.K. Factors affecting the levels of tea polyphenols and caffeine in tea leaves. J. Agric. Food Chem. 2003, 51, 1864–1873. [CrossRef] [PubMed]
11. Liu, M.; Tian, H.I.; Wu, J.H.; Cao, R.R.; Wang, R.X.; Qi, X.H.; Xu, Q.; Chen, X.H. Relationship between gene expression and the accumulation of catechin during spring and autumn in tea plants (Camellia sinensis L.). Hortic. Res. 2015, 2, 15011. [CrossRef] [PubMed]
12. Lantano, C.; Rinaldi, M.; Cavazza, A.; Barbanti, D.; Corradini, C. Effects of alternative steeping methods on composition, antioxidant property and colour of green, black and oolong tea infusions. J. Food Sci. Technol. 2015, 52, 8276–8283. [CrossRef] [PubMed]
13. Lambert, J.D.; Sang, S.; Yang, C.S. Biotransformation of green tea polyphenols and the biological activities of those metabolites. Mol. Pharm. 2007, 4, 819–825. [CrossRef] [PubMed]
14. Henning, S.M.; Niu, Y.; Lee, N.H.; Thames, G.D.; Minutti, R.R.; Wang, H.; Go, V.L.; Heber, D. Bioavailability and antioxidant activity of tea flavanoids after consumption of green tea, black tea, or a green tea extract supplement. Am. J. Clin. Nutr. 2004, 80, 1558–1564. [PubMed]
15. Stalmach, A.; Troufflard, S.; Serafini, M.; Crozier, A. Absorption, metabolism and excretion of Choladi green tea flavan-3-ols by humans. Mol. Nutr. Food Res. 2009, 53, S44–S53. [CrossRef] [PubMed]
16. Clifford, M.N.; van der Hooft, J.J.; Crozier, A. Human studies on the absorption, distribution, metabolism, and excretion of tea polyphenols. Am. J. Clin. Nutr. 2013, 98, 1619S–1630S. [CrossRef] [PubMed]
17. Lee, M.J.; Wang, Z.Y.; Li, H.; Chen, L.; Sun, Y.; Gobbo, S.; Balentine, D.A.; Yang, C.S. Analysis of plasma and urinary tea polyphenols in human subjects. Cancer Epidemiol. Biomark. Prev. 1995, 4, 393–399.
18. Yang, C.S.; Chen, L.; Lee, M.J.; Balentine, D.; Kuo, M.C.; Schantz, S.P. Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol. Biomark. Prev. 1998, 7, 351–354.
19. Chow, H.H.; Cai, Y.; Alberts, D.S.; Hakim, I.; Dorr, R.; Shahi, F.; Crowell, J.A.; Yang, C.S.; Hara, Y. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol. Biomark. Prev. 2001, 10, 53–58.
20. Van Amelsvoort, J.M.; Van Hof, K.H.; Mathot, J.N.; Mulder, T.P.; Wiersma, A.; Tijburg, L.B. Plasma concentrations of individual tea catechins after a single oral dose in humans. Xenobiotica 2001, 31, 891–901. [CrossRef] [PubMed]
21. Clarke, K.A.; Dew, T.P.; Watson, R.E.; Farrar, M.D.; Bennett, S.; Nicolaou, A.; Rhodes, L.E.; Williamson, G. High performance liquid chromatography tandem mass spectrometry dual extraction method for identification of green tea catechin metabolites excreted in human urine. J. Chromatogr. B Analyt. Techonol. Biomed. Life Sci. 2014, 1, 29–37. [CrossRef] [PubMed]
22. Chow, H.H.; Cai, Y.; Hakim, I.A.; Crowell, J.A.; Shahi, F.; Brooks, C.A.; Dorr, R.T.; Hara, Y.; Alberts, D.S. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin. Cancer Res. 2003, 9, 3312–3319. [PubMed]
23. Nakagawa, K.; Okuda, S.; Miyazawa, T. Dose-dependent incorporation of tea catechins, (−)-epigallocatechin-3-gallate and (−)-epigallocatechin, into human plasma. Biosci. Biotechnol. Biochem. 1997, 61, 1981–1985. [CrossRef] [PubMed]
24. Ullmann, U.; Haller, J.; Decourt, J.P.; Girault, N.; Girault, J.; Richard-Caudron, A.S.; Pineau, B.; Weber, P. A single ascending dose study of epigallocatechin gallate in healthy volunteers. J. Int. Med. Res. 2003, 31, 88–101. [CrossRef] [PubMed]
25. Reygaert, W.C. The antimicrobial possibilities of green tea. Front. Microbiol. 2014, 5, 434. [CrossRef] [PubMed]
26. Shirakami, Y.; Shimizu, M.; Moriwaki, H. Cancer chemoprevention with green tea catechins: From bench to bed. Curr. Drug Targets 2012, 13, 1842–1857. [CrossRef] [PubMed]
27. Henning, S.M.; Wang, P.; Carpenter, C.L.; Heber, D. Epigenetic effects of green tea polyphenols in cancer. Epigenomics 2013, 5, 729–741. [CrossRef] [PubMed]
28. Subramani, C.; Natesh, R.K. Molecular mechanisms and biological implications of green tea polyphenol, (−)-epigallocatechin-3-gallate. Int. J. Pharm. Biosci. Technol. 2013, 1, 54–63.
29. Butt, M.S.; Ahmad, R.S.; Sultan, M.T.; Qayyum, M.M.; Naz, A. Green tea and anticancer perspectives: Updates from last decade. Crit. Rev. Food Sci. Nutr. 2015, 55, 792–805. [CrossRef] [PubMed]
30. Granja, A.; Pinheiro, M.; Reis, S. Epigallocatechin gallate nanodelivery systems for cancer therapy. Nutrients 2016, 8, E307. [CrossRef]
31. Yang, C.S.; Wang, H.; Li, G.X.; Yang, Z.; Guan, F.; Jin, H. Cancer prevention by tea: Evidence from laboratory studies. Pharmacol. Res. 2011, 64, 113–122. [CrossRef] [PubMed]
32. Yang, C.S. Antioxidant and anti-carcinogenic activities of tea polyphenols. Arch. Toxicol. 2009, 83, 11–21. [CrossRef] [PubMed]
33. Ju, J.; Lu, G.; Lambert, J.D.; Yang, C.S. Inhibition of carcinogenesis by tea constituents. Semin. Cancer Biol. 2007, 17, 395–402. [CrossRef] [PubMed]
34. Boehm, K.; Borelli, F.; Ernst, E.; Habacher, G.; Hung, S.K.; Milazzo, S.; Hornebar, M. Green tea (Camellia sinensis) for the prevention of cancer. Cochrane Database Syst. Rev. 2009, 3. [CrossRef]
35. Bhoo-Pathy, N.; Peeters, P.H.; van Gils, C.; Beulens, J.W.; van der Graaf, Y.; Bueno-de-Mesquita, B.; Bulgiba, A.; Uiterwaal, C.S. Coffee and tea intake and risk of breast. Breast Cancer Res. Treat. 2010, 121, 461–467. [CrossRef] [PubMed]
36. Bode, A.M.; Dong, Z. Epigallocatechin 3-gallate and green tea catechins: United they work, divided they fall. Cancer Prev. Res. (Phila.) 2009, 2, 514–517. [CrossRef] [PubMed]
37. Li, M.J.; Yin, Y.C.; Wang, J.; Jiang, Y.F. Green tea compounds in breast cancer prevention and treatment. World J. Clin. Oncol. 2014, 5, 520–528. [CrossRef] [PubMed]
38. Umeda, D.; Yano, S.; Yamada, K.; Tachibana, H. Green tea polyphenol epigallocatechin-3-gallate signaling pathway through 67-kDa laminin receptor. J. Biol. Chem. 2008, 283, 3050–3058. [CrossRef] [PubMed]
39. Liang, Y.C.; Lin-Shiau, S.Y.; Chen, C.F.; Lin, J.K. Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (−)-epigallocatechin-3-gallate. J. Cell. Biochem. 1999, 75, 1–12. [CrossRef]
40. Bain, J.; McLauchlan, H.; Elliott, M.; Cohen, P. The specificities of protein kinase inhibitors: An update. Biochemistry 2003, 371 Pt 1, 199–204.
41. Farabegoli, F.; Papi, A.; Orlandi, M. (−)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells. Biosci. Rep. 2011, 31, 99–108. [CrossRef] [PubMed]
42. De Amicis, F.; Russo, A.; Avena, P.; Santoro, M.; Vivacqua, D.; Bonofiglio, D.; Mauro, L.; Aquila, S.; Tramontano, D.; Fuqua, S.A.; Ando, S. In vitro mechanism for downregulation of ER-α expression by epigallocatechin gallate in ER+/PR+ human breast cancer cells. Mol. Nutr. Food Res. 2013, 57, 840–853. [CrossRef] [PubMed]
43. Kim, J.; Zhang, X.; Rieger-Christ, K.M.; Summerhaves, I.C.; Wazer, D.E.; Paulson, K.E.; Yee, A.S. Suppression of Wnt signaling by the green tea compound (−)-epigallocatechin 3-gallate (EGCG) in invasive breast cancer cells. Requirement of the transcriptional repressor HBP1. J. Biol. Chem. 2006, 281, 10865–10875. [CrossRef] [PubMed]
44. Pianetti, S.; Guo, S.; Kavanagh, K.T.; Sonenshein, G.E. Green tea polyphenol epigallocatechin-3-gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells. Cancer Res. 2002, 62, 652–655. [PubMed]
45. Masuda, M.; Suzui, M.; Lim, J.T.; Weinstein, I.B. Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. Clin. Cancer Res. 2003, 9, 3486–3491. [PubMed]
46. Bigelow, R.L.; Cardelli, J.A. The green tea catechins, (−)-epigallocatechin-3-gallate (EGCG) and (−)-epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells. Oncogene 2006, 25, 1922–1930. [CrossRef] [PubMed]
47. Li, M.; He, Z.; Ermakova, S.; Zheng, D.; Tang, F.; Cho, Y.Y.; Zhu, F.; Ma, W.Y.; Sham, Y.; Rogozin, E.A.; et al. Direct inhibition of insulin-like growth factor-I receptor kinase activity by (−)-epigallocatechin-3-gallate regulates cell transformation. Cancer Epidemiol. Biomark. Prev. 2007, 16, 598–605. [CrossRef] [PubMed]
48. Van Aller, G.S.; Carson, J.D.; Tang, W.; Peng, H.; Zhao, L.; Copeland, R.A.; Tummino, P.J.; Luo, L. Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor. Biochem. Biophys. Res. Commun. 2011, 406, 194–199. [CrossRef] [PubMed]
49. Masuda, M.; Suzui, M.; Lim, J.T.; Deguchi, A.; Soh, J.W.; Weinstein, I.B. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. J. Exp. Ther. Oncol. 2002, 2, 350–359. [CrossRef] [PubMed]
50. Sartippour, M.R.; Shao, Z.M.; Heber, D.; Beatty, P.; Zhang, L.; Liu, C.; Go, V.L.; Brooks, M.N. Green tea inhibits vascular endothelial growth factor (VEGF) induction in human breast cancer cells. J. Nutr. 2002, 132, 2307–2311. [PubMed]
51. Braicu, C.; Gherman, C.D.; Irimie, A.; Berindan-Neagoe, I. Epigallocatechin-3-gallate (EGCG) inhibits cell proliferation and migratory behaviour of triple negative breast cancer cells. J. Nanosci. Nanotechnol. 2013, 13, 632–637. [CrossRef] [PubMed]
52. Ermakova, S.; Choi, B.Y.; Choi, H.S.; Kang, B.S.; Bode, A.M.; Dong, Z. The intermediate filament protein vimentin is a new target for epigallocatechin gallate. J. Biol. Chem. 2005, 280, 16882–16890. [CrossRef] [PubMed]
53. Leone, M.; Zhai, D.; Sareth, S.; Kitada, S.; Reed, J.C.; Pellecchia, M. Cancer prevention by tea polyphenols is linked to their inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res. 2003, 63, 8118–8121. [PubMed]
54. Islam, S.; Islam, N.; Kermode, T.; Johnstone, B.; Mukhtar, H.; Moskowitz, R.W.; Goldber, V.M.; Malemud, C.J.; Haqqi, T.M. Involvement of caspase-3 in epigallocatechin-3-gallate-mediated apoptosis of human chondrosarcoma cells. Biochem. Biophys. Res. Commun. 2000, 270, 793–797. [CrossRef] [PubMed]
55. Roy, A.M.; Baliga, M.S.; Katiyar, S.K. Epigallocatechin-3-gallate induces apoptosis in estrogen receptor-negative human breast carcinoma cells via modulation in protein expression of p53 and Bax and caspase-3 activation. Mol. Cancer Ther. 2005, 4, 81–90. [PubMed]
56. Alshatwi, A.A. Catechin hydrate suppresses MCF-7 proliferation through TP53/Caspase-mediated apoptosis. J. Exp. Clin. Cancer Res. 2010, 29, 167. [CrossRef] [PubMed]
57. Ermakova, S.P.; Kang, B.S.; Choi, B.Y.; Choi, H.S.; Schuster, T.F.; Ma, W.Y.; Bode, A.M.; Dong, Z. (−)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res. 2006, 66, 9260–9269. [CrossRef] [PubMed]
58. Jochmann, N.; Baumann, G.; Stangl, V. Green tea and cardiovascular disease: From molecular targets towards human health. Curr. Opin. Clin. Nutr. Metab. Care 2008, 11, 758–765. [CrossRef] [PubMed]
59. Nakachi, K.; Matsuyama, S.; Miyake, S.; Suganuma, M.; Imai, K. Preventive effects of drinking green tea on cancer and cardiovascular disease: Epidemiological evidence for multiple targeting prevention. Biofactors 2000, 13, 49–54. [CrossRef] [PubMed]
60. Kuriyama, S.; Shimazu, T.; Ohmori, K.; Kikuchi, N.; Nakaya, N.; Nishino, Y.; Tsubono, Y.; Tsuji, I. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: The Ohsaki study. JAMA 2006, 296, 1255–1265. [CrossRef] [PubMed]
61. Nagao, T.; Hase, T.; Tokimitsu, I. A green tea extract high in catechins reduces body fat and cardiovascular risks in humans. Obesity (Silver Spring) 2007, 15, 1473–1483. [CrossRef] [PubMed]
62. Fukino, Y.; Shimbo, M.; Aoki, N.; Okubo, T.; Iso, H. Randomized controlled trial for an effect of green tea consumption on insulin resistance and inflammation markers. J. Nutr. Sci. Vitaminol. (Tokyo) 2005, 51, 335–342. [CrossRef] [PubMed]
63. Peters, U.; Poole, C.; Arab, L. Does tea affect cardiovascular disease? A meta-analysis. Am. J. Epidemiol. 2001, 154, 495–503. [CrossRef] [PubMed]
64. Mukamal, K.J.; Maclure, M.; Muller, J.E.; Sherwood, J.B.; Mittleman, M.A. Tea consumption and mortality after acute myocardial infarction. Circulation 2002, 105, 2476–2481. [CrossRef] [PubMed]
65. Widlanski, M.E.; Hamburg, N.M.; Anter, E.; Holbrook, M.; Kahn, D.F.; Elliott, J.G.; Keaney, J.F., Jr.; Vita, J.A. Acute EGCG supplementation reverses endothelial dysfunction in patients with coronary artery disease. J. Am. Coll. Nutr. 2007, 26, 95–102. [CrossRef]
66. Ponzo, V.; Goitre, I.; Fadda, M.; Gambino, R.; De Francesco, A.; Soldati, L.; Gentile, L.; Magistroni, P.; Cassader, M.; Bo, S. Dietary flavonoid intake and cardiovascular risk: A population-based cohort study. J. Transl. Med. 2015, 13, 218. [CrossRef] [PubMed]
67. Serafini, M.; Del Rio, D.; Yao, D.N.; Bettuzzi, S.; Peluso, I. Chapter 12: Health benefits of tea. In Herbal Medicine: Biomolecular, and Clinical Aspects, 2nd ed.; Benzie, I.F.F., Wachtel-Galor, S., Eds.; CRC Press: Boca Raton, FL, USA, 2011; pp. 239–262.
68. Ahmed, S.; Marotte, H.; Kwan, K.; Ruth, J.H.; Campbell, P.L.; Rabquer, B.J.; Pakozdi, A.; Koch, A.E. Epigallocaetchin-3-gallate inhibits IL-6 synthesis and suppresses transsignaling by enhancing soluble gp130 production. Proc. Natl. Acad. Sci. USA 2008, 105, 14692–14697. [CrossRef] [PubMed]
69. Yun, H.J.; Yoo, W.H.; Han, M.K.; Lee, Y.R.; Kim, J.S.; Lee, S.I. Epigallocatechin-3-gallate suppresses TNF-α-induced production of MMP-1 and-3 in rheumatoid arthritis synovial fibroblasts. Rheumatol. Int. 2008, 29, 23–29. [CrossRef] [PubMed]
70. Leong, D.J.; Choudhury, M.; Hanstein, R.; Hirsh, D.M.; Kim, S.J.; Majeska, R.J.; Schaffler, M.B.; Hardin, J.A.; Spray, D.C.; Goldring, M.B.; et al. Green tea polyphenol treatment is chondroprotective, anti-inflammatory and palliative in a mouse posttraumatic osteoarthritis model. Arthritis Res. Ther. 2014, 16, 508. [CrossRef] [PubMed]
71. Naito, Y.; Yoshikawa, T. Green tea and heart health. J. Cardiovasc. Pharmacol. 2009, 54, 385–390. [CrossRef] [PubMed]
72. Liu, D.; Perkins, J.T.; Hennig, B. EGCG prevents PCB-126-induced endothelial cell inflammation via epigenetic modifications of NF-κB target genes in human endothelial cells. J. Nutr. Biochem. 2016, 28, 164–170. [CrossRef] [PubMed]
73. Donà, M.; Dell’Aica, I.; Calabrese, F.; Benelli, R.; Morini, M.; Albini, A.; Garbisa, S. Neutrophil restraint by green tea: Inhibition of inflammation, associated angiogenesis, and pulmonary fibrosis. J. Immunol. 2003, 170, 4335–4341. [CrossRef] [PubMed]
74. Akhtar, N.; Haqqi, T.M. Epigallocatechin-3-gallate suppresses the global interleukin-1beta-induced inflammatory response in human chondrocytes. Arthritis Res. Ther. 2011, 13, r93. [CrossRef] [PubMed]
75. Behfarnia, P.; Aslani, A.; Jamshidian, F.; Noohi, S. The efficacy of green tea chewing gum on gingival inflammation. J. Dent. Shiraz Univ. Med. Sci. 2016, 17, 149–154.
76. Kim, I.B.; Kim, D.Y.; Lee, S.J.; Sun, M.J.; Lee, M.S.; Li, H.; Cho, J.J.; Park, C.S. Inhibition of IL-8 production by green tea polyphenols in human nasal fibroblasts and A549 epithelial cells. Biol. Pharm Bull. 2006, 29, 1120–1125. [CrossRef] [PubMed]
77. 4-receptor gene expression by interferon-γ in vascular endothelial cells. J. Pharmacol. Sci. 2008, 107, 419–427. [CrossRef] [PubMed]
78. Liu, X.; Zhang, D.Y.; Zhang, W.; Zhao, X.; Yuan, C.; Ye, F. The effect of green tea extract and EGCG on the signaling network in squamous cell carcinoma. Nutr. Cancer 2011, 63, 466–475. [CrossRef] [PubMed]
79. Baba, Y.; Sonoda, J.I.; Hayashi, S.; Tosuji, N.; Sonoda, S.; Makisumi, K.; Nakajo, M. Reduction of oxidative stress in liver cancer patients by oral green tea polyphenol tablets during hepatic arterial infusion chemotherapy. Exp. Ther. Med. 2012, 4, 452–458. [CrossRef] [PubMed]
80. Tao, L.; Forester, S.C.; Lambert, J.D. The role of the mitochondrial oxidative stress in the cytotoxic effects of the green tea catechin, (−)-epigallocatechin-3-gallate, in oral cells. Mol. Nutr. Food Res. 2014, 58, 665–676. [CrossRef] [PubMed]
81. Calo, L.A.; Vertolli, U.; Davis, P.A.; Dal Maso, L.; Pagnin, E.; Ravarotto, V.; Maiolino, G.; Lupia, M.; Seccia, T.M.; Rossi, G.P. Molecular biology based assessment of green tea effects on oxidative stress and cardiac remodeling in dialysis patients. Clin. Nutr. 2014, 33, 437–442. [CrossRef] [PubMed]
82. Vester, H.; Holzer, N.; Neumaier, M.; Lilianna, S.; Nüssler, A.K.; Seeliger, C. Green tea extract (GTE) improves differentiation in human osteoblasts during oxidative stress. J. Inflamm. (Lond.) 2014, 11, 15. [CrossRef] [PubMed]
83. Sugita, M.; Kapoor, M.P.; Nishimura, A.; Okubo, T. Influence of green tea catechins on oxidative stress metabolites at rest and during exercise in healthy humans. Nutrition 2016, 32, 321–331. [CrossRef] [PubMed]
84. Jówko, E.; Sacharuk, J.; Balasinska, B.; Wilczak, J.; Charmas, M.; Ostraszewski, P.; Charmas, R. Effect of a single dose of green tea polyphenols on the blood markers of exercise-induced oxidative stress in soccer players. Int. J. Sport Nutr. Exerc. Metab. 2012, 22, 486–496. [CrossRef] [PubMed]
85. Zhao, J.; Fang, S.; Yuan, Y.; Guo, Z.; Zeng, J.; Guo, Y.; Tang, P.; Mei, X. Green tea polyphenols protect spinal cord neurons against hydrogen peroxide-induced oxidative stress. Neural Regen. Res. 2014, 9, 1379–1385. [PubMed]
86. Jówko, E.; Długołęcka, B.; Makaruk, B.; Cieśliński, I. The effect of green tea extract supplements on exercise-induced oxidative stress parameters in male sprinters. Eur. J. Nutr. 2015, 54, 783–791. [CrossRef] [PubMed]
87. Bogdanski, P.; Suliburska, J.; Szulinska, M.; Stepien, M.; Pupek-Musialik, D.; Jablecka, A. Green tea extract reduces blood pressure, inflammatory biomarkers, and oxidative stress and improves parameters associated with insulin resistance in obese, hypertensive patients. Nutr. Res. 2012, 32, 421–427. [CrossRef] [PubMed]
88. Li, M.; Liu, J.T.; Pang, X.M.; Han, C.J.; Mao, J.J. Epigallocatechin-3-gallate inhibits angiotensin II and interleukin-6-induced C-reactive protein production in macrophages. Pharmacol. Rep. 2012, 64, 912–918. [CrossRef]
89. Bhardwaj, P.; Khanna, D. Green tea catechins: Defensive role in cardiovascular disorders. Chin. J. Nat. Med. 2013, 11, 345–353. [CrossRef]
90. Son, D.J.; Cho, M.R.; Jin, Y.R.; Kim, S.Y.; Park, Y.H.; Lee, S.H.; Akiba, S.; Sato, T.; Yun, Y.P. Antiplatelet effect of green tea catechins: A possible mechanism through arachidonic acid pathway. Prostaglandins Leukot. Essent. Fatty Acids 2004, 71, 25–31. [CrossRef] [PubMed]
91. Jin, Y.R.; Im, J.H.; Park, E.S.; Cho, M.R.; Han, X.H.; Lee, J.J.; Lim, Y.; Kim, T.J.; Yun, Y.P. Antiplatelet activity of epigallocatechin gallate is mediated by the inhibition of PLCγ2 phosphorylation, elevation of PGD2 production, and maintaining calcium-ATPase activity. J. Cardiovasc. Pharmacol. 2008, 51, 45–54. [CrossRef] [PubMed]
92. Ok, W.J.; Cho, H.J.; Kim, H.H.; Lee, D.H.; Kang, H.Y.; Kwon, H.W.; Rhee, M.H.; Kim, M.; Park, H.J. Epigallocatechin-3-gallate has an anti-platelet effect in a cyclic AMP-dependent manner. J. Atheroscler. Thromb. 2012, 19, 337–348. [CrossRef] [PubMed]
93. Lee, D.H.; Kim, Y.J.; Kim, H.H.; Cho, H.J.; Ryu, J.H.; Rhee, M.H.; Park, H.J. Inhibitory effects of epigallocatechin-3-gallate on microsomal cyclooxygenase-1 activity in platelets. Biomol. Ther. 2013, 21, 54–59. [CrossRef] [PubMed]
94. Iida, Y.; Doi, T.; Matsushima-Nishiwaki, R.; Tokuda, H.; Ogura, S.; Kozawa, O.; Iida, H. (−)-Epigallocatechin gallate selectively inhibits adenosine diphosphate-stimulated human platelet activation: Suppression of heat shock protein 27 phosphorylation via p38 mitogen-activated protein kinase. Mol. Med. Rep. 2014, 10, 1383–1388. [CrossRef] [PubMed]
95. Jain, K.S.; Kathiravan, M.K.; Somani, R.S.; Shisloo, C.J. The biology and chemistry of hyperlipidemia. Bioorg. Med. Chem. 2007, 15, 4674–4699. [CrossRef] [PubMed]
96. Parthasarathy, S.; Raghavamenon, A.; Gareinabi, M.O.; Santanam, N. Oxidized low-density lipoprotein. Methods Mol. Biol. 2010, 610, 403–417. [PubMed]
97. Kim, A.; Chiu, A.; Barone, M.K.; Avino, D.; Wang, F.; Coleman, C.I.; Phung, O.J. Green tea catechins decrease total and low-density lipoprotein cholesterol: A systematic review and meta-analysis. J. Am. Diet. Assoc. 2011, 111, 1720–1729. [CrossRef] [PubMed]
98. Zheng, X.X.; Xu, Y.L.; Li, S.H.; Liu, X.X.; Hui, R.; Huang, X.H. green tea intake lowers fasting serum total and LDL cholesterol in adults: A meta-analysis of 14 randomized controlled trials. Am. J. Clin. Nutr. 2011, 94, 601–610. [CrossRef] [PubMed]
99. Wu, A.H.; Spicer, D.; Stanczyk, F.Z.; Tseng, C.C.; Yang, C.S.; Pike, M.C. Effect of 2 month controlled green tea intervention on lipoprotein cholesterol, glucose, and hormone levels in healthy postmenopausal women. Cancer Prev. Res. (Phila.) 2012, 5, 393–402. [CrossRef] [PubMed]
100. Khalesi, S.; Sun, J.; Buys, N.; Jamashidi, A.; Nikbakht-Nasrabadi, E.; Khosravi-Boroujeni, H. Green tea catechins and blood pressure: A systematic review and meta-analysis of randomized controlled trials. Eur. J. Nutr. 2014, 53, 1299–1311. [CrossRef] [PubMed]
101. Ohmori, R.; Kondo, K.; Momiyama, Y. Antioxidant beverages: Green tea intake and coronary artery disease. Clin. Med. Insights Cardiol. 2014, 8 (Suppl. 3), 7–11. [CrossRef] [PubMed]
102. Onakpoya, I.; Spencer, E.; Heneghan, C.; Thompson, M. The effect of green tea on blood pressure and lipid profile: A systematic review and meta-analysis of randomized clinical trials. Nutr. Met. Cardiovasc. Dis. 2014, 24, 823–836. [CrossRef] [PubMed]
103. Takechi, R.; Alfonso, H.; Hiramatsu, N.; Ishisaka, A.; Tanaka, A.; Tan, L.B.; Lee, A.H. Elevated plasma and urinary concentrations of green tea catechins associated with improved plasma lipid profile in healthy Japanese women. Nutr. Res. 2016, 36, 220–226. [CrossRef] [PubMed]
104. Tian, C.; Huang, Q.; Yang, L.; Légaré, S.; Angileri, F.; Yang, H. Green tea consumption is associated with reduced incident CHD and improved CHD-related biomarkers in the Dongfeng-Tongji cohort. Sci. Rep. 2016, 6, 24353. [CrossRef] [PubMed]
105. Suzuki-Sugihara, N.; Kishimoto, Y.; Saita, E.; Taguchi, C.; Kobayashi, M.; Ichitani, M.; Ukawa, Y.; Sagesaka, Y.M.; Suzuki, E.; Kondo, K. Green tea catechins prevent low-density lipoprotein oxidation via their accumulation in low-density lipoprotein particles in humans. Nutr. Res. 2016, 36, 16–23. [CrossRef] [PubMed]
106. Reygaert, W.C. Potential for Prevention of Infection by Green Tea. In Green Tea and Health: Antioxidant Properties, Consumption and Role in Disease Prevention; Powell, N., Ed.; Nova Science Pub Inc.: Hauppauge, NY, USA, 2015.
107. Gaur, S.; Agnihotri, R. Green tea: A novel functional food for the oral health of older adults. Geriatr. Gerontol. Int. 2014, 14, 238–250. [CrossRef] [PubMed]
108. Awadalla, H.I.; Ragab, M.H.; Bassuoni, M.W.; Fayed, M.T.; Abbas, M.O. A pilot study of the role of green tea use on oral health. Int. J. Dent. Hyg. 2011, 9, 110–116. [CrossRef] [PubMed]
109. Rassameemasmaung, S.; Phusudsawang, P.; Sangalungkarn, V. Effect of green tea mouthwash on oral malodor. ISRN Prev. Med. 2012, 2013, 975148. [CrossRef] [PubMed]
110. Kushiyama, M.; Shimazaki, Y.; Murakami, M.; Yamashita, Y. Relationship between intake of green tea and periodontal disease. J. Periodontol. 2009, 80, 372–377. [CrossRef] [PubMed]
111. Kato, M.T.; Magalháes, A.C.; Rios, D.; Hannas, A.R.; Attin, T.; Buzalaf, M.A. Protective effect of green tea on dentin erosion and abrasion. J. Appl. Oral Sci. 2009, 17, 560–564. [CrossRef] [PubMed]
112. Hara, K.; Ohara, M.; Hayashi, I.; Hino, T.; Nishimura, R.; Iwasaki, Y.; Ogawa, T.; Ohyama, Y.; Sugiyama, M.; Amano, H. The green tea polyphenol (−)-epigallocatechin gallate precipitates salivary proteins including alpha-amylase: Biochemical implications for oral health. Eur. J. Oral Sci. 2012, 120, 132–139. [CrossRef] [PubMed]
113. Narotzki, B.; Levy, Y.; Aizenbud, D.; Reznick, A.Z. Green tea and its major polyphenol EGCG increase the activity of oral peroxidases. Adv. Exp. Med. Biol. 2013, 756, 99–104. [PubMed]